← Back to Search

GM T Cell Therapy Long-Term Follow-Up for Cancer

Pamplona, Spain
Phase 2 & 3
Recruiting
Research Sponsored by Celgene
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Received at least one gene-modified (GM) T-cell infusion in a previous Celgene sponsored or Celgene alliance partner-sponsored study, and have discontinued, or completed the post-treatment follow-up period in the parent treatment protocol, as applicable
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 15 years
Awards & highlights
No Placebo-Only Group

Summary

This trial will follow up on participants who received gene-modified T cell therapy in a previous study to see if the therapy is safe and effective in the long term.

Who is the study for?
This trial is for pediatric and adult patients who have previously received gene-modified (GM) T cell therapy in a Celgene sponsored or alliance partner study. Participants must have completed or discontinued the prior treatment protocol and be willing to sign an informed consent form.
What is being tested?
The study focuses on long-term follow-up of safety and efficacy for those who underwent GM T cell therapy. It's designed to monitor participants after they've finished their initial treatment, tracking any long-term effects.
What are the potential side effects?
Since this is a follow-up study, it will observe side effects from previous GM T cell therapy which may include immune reactions, infusion-related symptoms, and potential late-onset complications.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I've had a gene-modified T-cell infusion in a past Celgene study and completed the follow-up.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 15 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 15 years for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Secondary study objectives
B-Lymphocytes

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

1Treatment groups
Experimental Treatment
Group I: Participants exposed to Gene-modified (GM) T cell therapyExperimental Treatment1 Intervention

Find a Location

Closest Location:Local Institution - 01060· Seattle, WA

Who is running the clinical trial?

CelgeneLead Sponsor
645 Previous Clinical Trials
129,867 Total Patients Enrolled
1 Trials studying Tumors
107 Patients Enrolled for Tumors
Claudia Schusterbauer, MDStudy DirectorCelgene Corporation
3 Previous Clinical Trials
146 Total Patients Enrolled
Bristol-Myers SquibbStudy DirectorBristol-Myers Squibb
1,582 Previous Clinical Trials
3,388,284 Total Patients Enrolled
8 Trials studying Tumors
422 Patients Enrolled for Tumors

Media Library

Participants exposed to Gene-modified (GM) T cell therapy Clinical Trial Eligibility Overview. Trial Name: NCT03435796 — Phase 2 & 3
Tumors Research Study Groups: Participants exposed to Gene-modified (GM) T cell therapy
Tumors Clinical Trial 2023: Participants exposed to Gene-modified (GM) T cell therapy Highlights & Side Effects. Trial Name: NCT03435796 — Phase 2 & 3
Participants exposed to Gene-modified (GM) T cell therapy 2023 Treatment Timeline for Medical Study. Trial Name: NCT03435796 — Phase 2 & 3
~204 spots leftby Nov 2036